Hyperfine, Inc.

NasdaqGM:HYPR Stock Report

Market Cap: US$119.4m

Hyperfine Valuation

Is HYPR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HYPR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HYPR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HYPR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HYPR?

Key metric: As HYPR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HYPR. This is calculated by dividing HYPR's market cap by their current revenue.
What is HYPR's PS Ratio?
PS Ratio12.5x
SalesUS$10.80m
Market CapUS$119.44m

Price to Sales Ratio vs Peers

How does HYPR's PS Ratio compare to its peers?

The above table shows the PS ratio for HYPR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average13.6x
PDEX Pro-Dex
1.6xn/aUS$110.4m
LNSR LENSAR
2.5x27.83%US$144.2m
OBIO Orchestra BioMed Holdings
50x56.70%US$149.5m
KEQU Kewaunee Scientific
0.5xn/aUS$125.2m
HYPR Hyperfine
12.5x21.86%US$119.4m

Price-To-Sales vs Peers: HYPR is good value based on its Price-To-Sales Ratio (12.5x) compared to the peer average (13.6x).

Price to Sales Ratio vs Industry

How does HYPR's PS Ratio compare vs other companies in the US Medical Equipment Industry?

56 CompaniesPrice / SalesEstimated GrowthMarket Cap
XRAY DENTSPLY SIRONA
0.7x2.36%US$2.50b
QDEL QuidelOrtho
0.7x2.60%US$2.01b
ENOV Enovis
0.8x6.38%US$1.79b
IART Integra LifeSciences Holdings
0.7x4.32%US$1.13b
HYPR 12.5xIndustry Avg. 2.8xNo. of Companies56PS03.26.49.612.816+
56 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HYPR is expensive based on its Price-To-Sales Ratio (12.5x) compared to the US Medical Equipment industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is HYPR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HYPR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.5x
Fair PS Ratio1.6x

Price-To-Sales vs Fair Ratio: HYPR is expensive based on its Price-To-Sales Ratio (12.5x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HYPR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.72
US$1.42
-17.64%
33.15%US$2.00US$0.85n/a3
Oct ’26US$1.42
US$1.42
-0.23%
33.15%US$2.00US$0.85n/a3
Sep ’26US$1.24
US$1.42
+14.25%
33.15%US$2.00US$0.85n/a3
Aug ’26US$1.03
US$1.06
+2.91%
31.83%US$1.50US$0.68n/a3
Jul ’26US$0.69
US$1.06
+54.20%
31.83%US$1.50US$0.68n/a3
Jun ’26US$0.60
US$0.98
+63.07%
32.73%US$1.50US$0.68n/a4
May ’26US$0.73
US$1.30
+77.74%
9.45%US$1.50US$1.20n/a4
Apr ’26US$0.70
US$1.30
+85.09%
9.45%US$1.50US$1.20n/a4
Mar ’26US$0.97
US$1.20
+23.71%
18.00%US$1.50US$1.00n/a3
Feb ’26US$1.10
US$1.23
+12.12%
16.66%US$1.50US$1.00n/a3
Jan ’26US$0.88
US$1.23
+40.15%
16.66%US$1.50US$1.00n/a3
Dec ’25US$1.01
US$1.23
+22.11%
16.66%US$1.50US$1.00n/a3
Nov ’25US$0.98
US$1.23
+25.85%
16.66%US$1.50US$1.00n/a3
Oct ’25US$1.02
US$1.23
+20.91%
16.66%US$1.50US$1.00US$1.423
Sep ’25US$1.01
US$1.23
+22.11%
16.66%US$1.50US$1.00US$1.243
Aug ’25US$1.16
US$1.27
+9.20%
22.64%US$1.60US$0.90US$1.033
Jul ’25US$0.92
US$1.27
+37.89%
22.64%US$1.60US$0.90US$0.693
Jun ’25US$0.84
US$1.27
+51.52%
22.64%US$1.60US$0.90US$0.603
May ’25US$0.80
US$1.30
+62.28%
18.84%US$1.60US$1.00US$0.733
Apr ’25US$1.01
US$1.38
+36.96%
11.17%US$1.60US$1.25US$0.703
Mar ’25US$1.11
US$1.68
+51.65%
20.63%US$2.10US$1.25US$0.973
Feb ’25US$1.08
US$1.68
+55.86%
20.63%US$2.10US$1.25US$1.103
Jan ’25US$1.12
US$1.68
+50.30%
20.63%US$2.10US$1.25US$0.883
Dec ’24US$1.33
US$1.68
+25.94%
25.37%US$2.10US$1.25US$1.012
Nov ’24US$1.27
US$2.95
+132.28%
18.64%US$3.50US$2.40US$0.982
Oct ’24US$2.05
US$2.95
+43.90%
18.64%US$3.50US$2.40US$1.022
US$1.42
Fair Value
21.4% overvalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/07 23:35
End of Day Share Price 2025/10/07 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hyperfine, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuan ZhiB. Riley Securities, Inc.
Vijay KumarEvercore ISI
Frank TakkinenLake Street Capital Markets, LLC